Actonel
Product Images NDC 0430-0477

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Actonel (NDC 0430-0477). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Allergan, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Actonel 01

Chemical structure of the active ingredient in Actonel, showing a pyridine ring attached to a phosphate group with sodium and water molecules indicated as part of the compound.*

FDA Label Image

Actonel 02

A bar chart comparing the percentage of patients with fractures at different body sites between placebo and Actonel 5 mg groups. The chart shows data for All fractures, Wrist, Humerus, Hip, Pelvis, Leg, and Clavicle, with separate bars for placebo and Actonel 5 mg for each category.*

FDA Label Image

Actonel 03

A bar chart comparing the mean percentage change in Bone Mineral Density (BMD) with standard error (SE) across three anatomical sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. The chart contrasts results for placebo and Actonel 5 mg groups, with sample sizes (n) indicated for each site and treatment group.*

FDA Label Image

Actonel 04

A bar chart comparing the mean percent change in bone mineral density (BMD) at three anatomical sites: lumbar spine, femoral neck, and femoral trochanter. The chart contrasts the results for placebo versus Actonel 5 mg treatment, showing the number of subjects (n) for each group at each site.*

FDA Label Image

Actonel 05

A bar chart comparing the mean percentage change in bone mineral density (BMD) ± standard error in three anatomical sites: Lumbar Spine, Femoral Neck, and Femoral Trochanter. The chart contrasts Placebo and Actonel 5 mg groups, showing sample sizes for each group and site.*

FDA Label Image

Actonel 06

A bar chart comparing the incidence percentage for placebo and ACTONEL 5 mg in three patient groups: those continuing glucocorticoid treatment, those initiating glucocorticoid treatment, and a combined group. The chart labels number of patients (n) for each treatment and group.*

FDA Label Image

Actonel 07

A line graph comparing the percentage change over visit days between DIDRONEL 400 mg and ACTONEL 30 mg. The x-axis represents visit days grouped into Treatment, Follow-Up, and Extended Follow-Up periods, while the y-axis shows percentage change with measurements and sample sizes noted. The graph includes error bars reflecting variability in the data.*

FDA Label Image

Actonel 08

Actonel 5 mg (risedronate sodium) tablets packaging label displaying the product name, strength, dosage form, quantity of 30 tablets, NDC 0430-0471-15, and the labeler Allergan, Inc. The label instructs to dispense the enclosed medication guide to each patient.*

FDA Label Image

Actonel 09

Actonel 30 mg (risedronate sodium) tablets label showing 30 tablets per package. The label includes the NDC 0430-0470-15 and instructions to dispense the enclosed Medication Guide to each patient. The labeler is Allergan, Inc.*

FDA Label Image

Actonel 0a

Packaging label for Actonel 35 mg (risedronate sodium) tablets by Allergan, Inc. The label indicates a 4-week supply containing 4 tablets for once-a-week use. It includes the product name, strength, dosage form, and instruction to dispense the enclosed Medication Guide to each patient. The NDC number 0430-0472-03 is visible on the label.*

FDA Label Image

Actonel 0b

Actonel 35 mg (risedronate sodium) tablets packaging label for a 12-week supply. The label includes the product name, strength, active ingredient, dosage form, and directions to dispense the enclosed Medication Guide to each patient. The labeler is Allergan, Inc.*

FDA Label Image

Actonel 0c

Actonel 75 mg tablets one month pack containing 2 tablets. The label includes dosing instructions to take tablets on two consecutive days each month, with emphasis on swallowing the tablet whole with 6 to 8 ounces of plain water on the first day, and repeating the same on the second day. The labeler is Allergan, Inc.*

FDA Label Image

Actonel 0d

Box packaging label for Actonel (risedronate sodium) tablets 150 mg by Allergan, Inc. The label indicates a one-month pack containing one tablet with once-a-month dosing instructions. The design includes the Actonel logo, dosage strength, and a note to dispense the enclosed Medication Guide to each patient.*

FDA Label Image

Actonel 0e

Actonel 150 mg (risedronate sodium) tablets package, labeled as a 3 Month Pack with once-a-month dosing. The carton shows the brand name, active ingredient, strength, dosage form, and a note to dispense the enclosed Medication Guide to each patient. Manufactured by Allergan, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.